656 related articles for article (PubMed ID: 26138583)
1. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid treatment in children with osteogenesis imperfecta.
Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O
Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
4. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
[TBL] [Abstract][Full Text] [Related]
6. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
Shah I; Johari A
Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
[TBL] [Abstract][Full Text] [Related]
8. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
[TBL] [Abstract][Full Text] [Related]
9. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
10. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
Barros ER; Saraiva GL; de Oliveira TP; Lazaretti-Castro M
J Pediatr Endocrinol Metab; 2012; 25(5-6):485-91. PubMed ID: 22876543
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
13. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
14. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
15. Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle.
Tsimicalis A; Boitor M; Ferland CE; Rauch F; Le May S; Carrier JI; Ngheim T; Bilodeau C
Eur J Pediatr; 2018 Jun; 177(6):891-902. PubMed ID: 29637375
[TBL] [Abstract][Full Text] [Related]
16. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
Feehan AG; Zacharin MR; Lim AS; Simm PJ
Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
[TBL] [Abstract][Full Text] [Related]
18. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate therapy for osteogenesis imperfecta.
Phillipi CA; Remmington T; Steiner RD
Cochrane Database Syst Rev; 2008 Oct; (4):CD005088. PubMed ID: 18843680
[TBL] [Abstract][Full Text] [Related]
20. [Effects of zoledronic acid in adults with osteogenesis imperfecta].
Pavón de Paz I; Iglesias Bolaños P; Durán Martínez M; Olivar Roldán J; Guijarro De Armas G; Parra García JI
Endocrinol Nutr; 2010; 57(6):245-50. PubMed ID: 20510658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
